Moderna stock falls over 7% as heavy selling hits despite positive cancer vaccine data

Traders Union
All News
Stocks
Moderna slides 7.17% today to $147.44

Highlights

Moderna and Merck announced their personalized mRNA cancer vaccine met the primary endpoint in the INTerpath-001 Phase 3 trial with significant melanoma recurrence reduction.
Wall Street analysts issued upgrades for Moderna as the company advances intismeran to additional cancer indications and eyes potential commercial launch pending further data and regulatory approval.
Shares of Moderna slipped 7.17% to $147.44 despite strong technical momentum, with an expected five-day trading range of $131.06 to $163.82 and a high probability of price consolidation or advance.

Analyst upgrades and future prospects weighed against persistent sell pressure

Moderna Inc. reported positive Phase 3 clinical trial results for its personalized mRNA cancer vaccine, developed in partnership with Merck. The INTerpath-001 trial met its primary endpoint by showing a significant reduction in melanoma recurrence among patients, marking the first successful late-stage outcome for an mRNA-based cancer vaccine. These results led to subsequent Wall Street analyst upgrades and further research into intismeran in additional cancer indications, with a potential future commercial launch considered if later data and regulatory review remain favorable, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes the sharp 7.17% drop in Moderna despite positive Phase 3 trial news signals a disconnect between sentiment and fundamentals. He sees the heavy selloff, elevated volatility, and overbought technicals (RSI at 72.5) as warning signs, especially with price plunging toward the session low. Kharitonov cautions that the stock's bullish trend has not shielded it from aggressive profit-taking as traders respond to stretched conditions. He points to broad selling pressure overshadowing recent analyst upgrades and vaccine progress. "This move exposes downside risk — when overbought sentiment collides with strong news, defensive positioning is essential until buyer conviction rebounds."

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s positive Phase 3 news as a game-changer for long-term prospects. He highlights that analyst upgrades and strong research interest reinforce institutional confidence despite the recent dip. Karapetjanc stresses that the bullish structure remains intact with the stock well above key moving averages and a low probability of further sustained downside. "I believe further growth is ahead — our constructive outlook is supported by meaningful clinical advances and resilient technical support."

Parshwa Turakhiya, analyst, observes that short-term sentiment turned sharply negative intraday, but the overall uptrend is supported by strong momentum signals. He sees the heavy selloff as a setup for short-term volatility trades around support at $146.91 while noting overbought signals require risk management. Turakhiya suggests traders may find opportunities if price consolidates or rebounds toward $156.13. "In my view, this volatility creates tactical openings for nimble positioning — but overextended momentum means discipline is key."

Strong technical momentum challenged by volatility and overbought signals

Moderna is trading firmly above its 20-day, 50-day, and 200-day moving averages at $81.88, $71.57, and $49.98, indicating strength across short-, medium-, and long-term trends. The near-term ceiling is set at $156.13 and the near-term floor at $146.91, with broader trend confirmation supported by a bullish alignment between the 50-day and 200-day averages. Momentum remains strong as both the MACD and ADX suggest sustained buyer momentum. However, the RSI at 72.5 signals overbought conditions, and both the CCI and Bull/Bear Power also highlight an overstretched market. BBP above zero confirms buyers control intraday momentum, but these overbought readings indicate caution is warranted. The Awesome Oscillator supports the ongoing uptrend. During the last session, Moderna slipped $11.39 or 7.17% after a downside gap of $4.31 (2.71%), and the price is currently near the session low amid elevated intraday volatility of 6.28%. The intraday drop reflects significant sell pressure that stands in partial contrast to the otherwise positive momentum indicators.

Previously it was reported that Moderna shares broke out decisively following strong Phase 3 trial results for its personalized mRNA cancer vaccine, signaling robust upward momentum. The latest reversal introduces volatility to the outlook, and traders should closely monitor whether the $146.91 support level holds as a pivot for the next directional move.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.